Posts Categorized: Ending Sex Discrimination

Democratic War On Women Becomes A Friendly Fire Zone

Terry O’Neill, president of the National Organization for Women, noted that Democrats are leading the policy fight for legislation that would bar employers from refusing to accommodate pregnancies. “It’s completely in my view outrageous that the Democratic caucus wouldn’t make an accommodation for Tammy Duckworth,” O’Neill told BuzzFeed News. “That is an issue of public… Read more »

Statement of NOW President Terry O’Neill on the 2014 Congressional Elections

The latest statement from the National Organization for Women regarding the 2014 Congressional election results.

Outrage grows over Bridgewater State keeping rapes secret

The head of a national women’s group says it’s “outrageous” that Bridgewater State University officials withheld the names of two men charged with rape on campus and did not notify students and staff about the incidents last month. “We know that rape is a serial crime,” said Terry O’Neill, president of the National Organization of Women based in Washington, D.C. “The names of the accused rapists really need to be made public.”

NOW is the time for change

O’Neill’s passion about public policy that works for the benefit of women is evident. She talks about every point with a conviction that seems born directly out of personal experience. While much of our conversation focused on economic justice, that’s just one of the six core issues NOW works to change. Constitutional equality, reproductive rights, racial justice, LGBT rights, and ending violence against women are also high on the NOW priority list. O’Neill says the equality for women can’t truly be achieved unless all of those issues are addressed.

FDA Moves Toward More Women in Research Trials

The Food and Drug Administration (FDA) recently issued guidelines suggesting that more women, as well as greater racial, ethnic and age diversity, be included in research trials by companies submitting drug and device applications for review and approval. Unfortunately, the agency stopped short of requiring that companies have greater diversity in their study populations and to study the drug’s effects in those sub-populations.